Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsExtended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.
Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.
1.
Should the UK introduce targeted prostate cancer screening? The case for and against
2.
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
3.
Radiotherapy of cancer: Researchers enable better cancer treatment using existing medical equipment
4.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
5.
Older Adults With Advanced Cancer Prioritize Quality of Life
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
Cloud-Based Hematology Care Pathways: Integrating Digital Transformation in Blood Disorders Management
3.
The Capmist DM: A Revolutionary Way to Combat Dry Mouth
4.
Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC
5.
The Unseen Threat: Uncovering the Risks of Pancoast Tumor
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge